top of page

BHP Insights


Recent Trends in Medtech Deal Activity
Medtech deal activity has shifted from broad recovery to concentrated selectivity. Total M&A values climbed from ~$26B in 2023 to ~$61B in 2025, yet fewer deals are driving the numbers. Capital is flowing to milestone-proven assets, deal structures increasingly favor performance-based payments over upfront cash, and portfolio reshaping is accelerating. Here's what the data reveals about where medtech is heading.
Apr 29


The Einstellung Effect in Life Sciences Innovation: is Precedence Preventing Progress?
Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.
Dec 8, 2025


Considering the Impact of WCAS's Dismissal on Private Equity and Life Sciences Investment
A judge's dismissal of Welsh, Carson, Anderson & Stowe from the FTC's antitrust case against US Anesthesia Partners is more than a courtroom footnote, it's a meaningful signal for private equity nationwide. Had WCAS been held liable for its portfolio company's conduct despite its minority stake, the precedent could have chilled investment across life sciences, an industry that depends heavily on private capital to fund innovation. We break down the case and its broader implic
May 14, 2024


Takeaways from JP Morgan Healthcare Conference 2024
Cautious optimism defined this year's JP Morgan Healthcare Conference, fueled by a flurry of Merger Monday deals, anticipated Fed rate cuts, and growing big pharma appetite for smaller biotech companies. We break down the key 2024 takeaways: an improving M&A landscape favoring 'large acquiring small,' a shift away from COVID-19 products toward novel mechanisms of action like ADCs and CAR-Ts, and AI's accelerating, bidirectional role in reshaping healthcare innovation and inve
Feb 14, 2024


Brooks Hill Partners Invests in Cellbricks
Brooks Hill Partners has invested in Cellbricks, a 3D bioprinting company transforming pharmaceutical research and clinical care.
Jan 26, 2023


Brooks Hill Partners Joins Raise for Macula Vision Systems
Brooks Hill Partners has joined early-stage financing for Macula Vision Systems, a company focused AI-driven clinical microscopy.
Nov 1, 2022
Interested in learning more?
bottom of page
